Real-world Experience with Sotorasib in KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer: Clinical Outcomes and Tolerability in the UK.
AIM: Sotorasib is an oral, potent, selective inhibitor. The UK RWE aligns with the results of CodeBreaK 200.
AIM: Sotorasib is an oral, potent, selective inhibitor. The UK RWE aligns with the results of CodeBreaK 200.
What the study was
- Study design
- Clinical Trial
- Population
- Patient/participant population (size not extracted)
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Clinical oncology (Royal College of Radiologists (Great Britain))
Why it surfaced
Scored 9/10 (Clinical Trial; novelty=2, relevance=3, design_quality=2, population_or_unmet_need=2). HIGH priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.